Phase 2
N=36
Cannabidiol in Youth Alcohol Use Disorder
Alcohol Use Disorder
Bottom Line
View on ClinicalTrials.gov: NCT05317546 ↗Enrolled (actual)
36
Serious AEs
0.0%
Results posted
Aug 2025
Primary outcome: Primary: Concentrations of Glx (i.e., Glutamate + Glutamine) — 18.76; 18.57 mmol/kg — p=0.33
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Cannabidiol (Drug)
- Age
- Pediatric, Adult · 16+ yrs
- Sex
- All
- Sponsor
- Medical University of South Carolina
- Primary completion
- Jun 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Concentrations of Glx (i.e., Glutamate + Glutamine) |
18.76; 18.57 | 0.33 |
| PRIMARY GABA+ |
4.25; 4.22 | 0.75 |
| PRIMARY Alcohol Cue Reactivity Neural Activation |
1.02; 0.87; 0.62; 0.35; 0.53; 0.56 | >0.05 |
| PRIMARY Heart Rate Variability |
0.84; 0.81 | 0.82 |
| PRIMARY PhenX Toolkit Alcohol Urges Questionnaire |
23.18; 21.40; 18.56; 17.63; 16.47; 15.50 | 0.21 |
Summary
The goal of this study is to test cannabidiol (CBD) as a potentially effective candidate medication for youth alcohol use disorder (AUD). To accomplish this goal, this study will use a randomized, double-blind, within-subjects crossover design. In counterbalanced order, 50 youth (ages 16-22) will receive 600 mg of CBD or placebo three hours before a neuroimaging and behavioral assessment paradigm. The total amount of time the participant will be in the study is approximately one month.
Eligibility Criteria
Age 16 to 22. Does or does not drink alcohol.
Data sourced from ClinicalTrials.gov (NCT05317546). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.